Arcus Biosciences (RCUS) presents a negative equity recovery posture under a liquidation lens, consistent with MFFAIS-reported CLV/LLV/OLV of approximately negative $105-108 million as of March 31, 2026. The balance sheet totals $997 million in assets against $473 million in total liabilities, yielding $524 million in book equity. However, under liquidation haircuts, the recovery calculus deteriorates materially. The dominant liquid asset is $876 million in cash equivalents and marketable securities (at fair value), which recovers near par under the liquidation lens. All other non-cash assets are of limited recovery value: PP&E of $38 million recovers at 50-70% (approximately $19-27 million); $61 million in other noncurrent assets (predominantly operating lease ROU assets and security deposits) recovers poorly; prepaid and receivables of approximately $26 million recover at 90-95%. Intangible and IP value is zero under the lens. On the liability side, $100 million in long-term debt (Hercules term loan, maturing September 2030, secured by substantially all assets) sits at face value with no haircut. Current liabilities of $209 million include $136 million classified as OtherLiabilitiesCurrent and $34 million of deferred revenue (ContractWithCustomerLiabilityCurrent) — both remain at face value on wind-up. Noncurrent liabilities of $119 million include $45 million of long-term deferred revenue and operating lease liabilities; these do not extinguish on liquidation. The aggregate liability stack at face value is approximately $473 million. Against haircut assets of roughly $900-920 million, the resulting net recovery to equity is modestly positive on paper, but this ignores the structured nature of deferred collaboration revenues: the $79 million total ContractWithCustomerLiability represents obligations to Gilead and Taiho that would either need to be returned or renegotiated on wind-up, reducing recoverable assets further. Operating cash burn of $138 million in Q1 2026 annualizes to approximately $550 million, and the company self-discloses funding through at least H2 2028 based on the $876 million investment portfolio. The $100 million Hercules facility (out of a $250 million total commitment) is secured by substantially all assets, including the marketable securities portfolio, establishing senior priority in any distress scenario. Accumulated deficit stands at $1.613 billion. The prior filing (10-K, December 31, 2025) reflects a full-year net loss of $353 million versus Q1 2026's $128 million net loss — the run-rate is consistent. No material changes to contractual obligations are reported quarter-over-quarter. The BIOSECURE Act risk regarding WuXi Biologics (sole manufacturer of two key compounds) is a contingent liability that does not appear on the balance sheet and is not XBRL-tagged.
▼ Community Notes